This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Low Leverage Stocks You Will Love on Valentine's Day
by Zacks Equity Research
Since debt-burden companies are risky to invest in, especially at times of market turmoil; risk-averse investors should go for low leverage stocks.
Pfizer Announces FDA Acceptance of NDA for NSCLC Candidate
by Zacks Equity Research
Pfizer's (PFE) regulatory applications seeking approval for tyrosine kinase inhibitor, lorlatininb, for treating second or later line NSCLC accepted in the United States, Europe and Japan.
FDA Okays J&J's Prostate Cancer Drug in First-Line Setting
by Zacks Equity Research
The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.
Solid Q4 Earnings Drive Pharma ETF Outlook
by Sweta Killa
Although pharma ETFs saw terrible trading over the past one month in the latest global market rout, the string of earnings beat bolstered confidence in the space.
Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study
by Zacks Equity Research
Glaxo's (GSK) ViiV Healthcare commences phase III study on combo regimen of dolutegravir and lamivudine for maintenance of viral suppression in HIV-1 infection patients treated with TAF-based regimen.
The Zacks Analyst Blog Highlights: CA, Quest Diagnostics, Pfizer, United Parcel and U.S. Bancorp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CA, Quest Diagnostics, Pfizer, United Parcel and U.S. Bancorp
FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up
by Zacks Equity Research
Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.
Wall Street See-Saws on Spike in Bond Yields: 5 Safest Bets
by Tirthankar Chakraborty
Rise in bond yields increased the opportunity cost of investing in other asset classes such as equities, thus, making them less attractive.
Pfizer Files for Xtandi in Early Stage Prostate Cancer
by Zacks Equity Research
Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.
Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the fourth quarter. Eliquis records solid sales.
Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod
by Zacks Equity Research
The FDA's label expansion approval for Allergan's (AGN) Avycaz marks its third therapeutic indication nod for the anti-infective drug in the United States.
Dow 30 Stock Roundup: BA, MSFT, AAPL, MCD, PFE, V Earnings Impress
by Swarup Gupta
The Dow experienced a mixed week, losing momentum over the first few days before rebounding over the next two.
The Zacks Analyst Blog Highlights: Pfizer, PayPal, Raytheon, Aetna and Kinder Morgan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, PayPal, Raytheon, Aetna and Kinder Morgan
Momenta Up on FDA's Amendment of McPherson Compliance Status
by Zacks Equity Research
Momenta's (MNTA) stock gains as investors were relieved after the FDA classified the outcome of fourth-quarter 2017 reinspection of Pfizer's McPherson facility as Voluntary Action Indicated.
Q4 Results Remain Positive, Market Dips
by Zacks Equity Research
Q4 Results Remain Positive, Market Dips
Markets Deeper in the Red, Q4 Reports Stay Healthy
by Mark Vickery
Keeping with Q4 earnings results, here are 4 leaders in their respective spaces and how well they have performed relative to expectations.
Pfizer (PFE) Stock Falls Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
Pfizer (PFE) beats expectations for both earnings and revenues in Q4 and issues an upbeat guidance for 2018. However, shares decline in pre-market trading.
Pfizer (PFE) Q4 Earnings & Sales Top, 2018 View Upbeat
by Zacks Equity Research
Pfizer (PFE) beat expectations for both earnings and revenues in Q4. It issued an upbeat guidance for 2018.
AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call
by Arpita Dutt
With AbbVie (ABBV) surpassing expectations in the fourth quarter, here's a look at a few important takeaways from the company's conference call.
Will Pfizer (PFE) Surpass Estimates This Earnings Season?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q4, genericization of key drugs and supply shortages in legacy Hospira products will hurt sales.
Pfizer's Rituxan Biosimilar Meets Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) biosimilar version of Roche's blockbuster leukemia drug, Rituxan/Mabthera, meets primary endpoint in phase III comparative trial.
Is a Beat in the Cards for AbbVie (ABBV) in Q4 Earnings?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q4.
Healthcare ETFs to Watch As Q4 Earnings Unfold
by Sweta Killa
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.
Merck Reports Positive Phase III Liver Cancer Data on Keytruda
by Zacks Equity Research
Merck (MRK), announces first time results from the phase II study evaluating the use Keytruda in patients with advanced hepatocellular carcinoma (HCC), previously treated with sorafenib.
Gilead Collaborates with Pfizer for Yescarta Combo Study
by Zacks Equity Research
Kite, a Gilead Company (GILD), announced that it inked a clinical trial collaboration with Pfizer, for combination study.